Invivyd (IVVD) EBITDA Margin (2024 - 2025)
Invivyd (IVVD) posted EBITDA Margin of 72.96% for Q4 2025, up 13.1% on a QoQ basis from 83.96% in Q3 2025, and up 6617.0% year-over-year from 1.09% in Q4 2024.
Invivyd (IVVD) EBITDA Margin (2024 - 2025) Analysis & Trends
Invivyd's EBITDA Margin history runs 2 years deep, the most recent figure standing at 72.96% for Q4 2025.
- Quarterly EBITDA Margin rose 6617.0% year-over-year to 72.96% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 103.99% (up 59281.0% YoY) and the FY2025 annual result came in at 103.99%, up 59281.0% from the prior year.
- EBITDA Margin was 72.96% for Q4 2025 at Invivyd, up from 83.96% in the prior quarter.
- Across five years, EBITDA Margin topped out at 72.96% in Q4 2025 and bottomed at 2175.22% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn | -72.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -72.96% |
| Sep 30, 2025 | -83.96% |
| Jun 30, 2025 | -127.78% |
| Mar 31, 2025 | -149.70% |
| Dec 31, 2024 | -139.14% |
| Sep 30, 2024 | -670.01% |
| Jun 30, 2024 | -2,175.22% |